Since Th17 axis has been implicated as a hallmark of infectious diseases and inflammatory bowel diseases (IBD), our discovery of STING-controlled Th17 immunity provides new insights into the pathogenesis of IBD and potential interventional target for future therapy. This evidence concerns the gene STING1 and inflammatory bowel disease.